Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

January 04, 2013

Treating estrogen receptor–positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

December 22, 2012

Although the association between VEGF and ovarian cancer has been known for quite some time, researchers are still struggling to use drugs that inhibit VEGF and angiogenesis in patients with the disease.

March 14, 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses what Separates MSKCC From Other Top Cancer Centers Worldwide